Outcomes improved for metastatic castration-resistant prostate cancer that is positive for prostate-specific membrane antigen
MONDAY, June 7, 2021 (HealthDay News) — For previously treated metastatic castration-resistant prostate cancer (mCRPC) that is positive for prostate-specific membrane antigen (PSMA), 177Lu-PSMA-617 plus standard of care (SOC) improves radiographic progression-free survival (rPFS) and overall survival compared with SOC alone, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held virtually from June 4 to 8.
Michael J. Morris, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues conducted a randomized phase 3 trial evaluating 177Lu-PSMA-617 in men with PSMA-positive mCRPC that was previously treated with antiandrogen therapy and chemotherapy. Participants were randomly assigned to 177Lu-PSMA-617 plus SOC or SOC alone (551 and 280, respectively). Participants had been followed for a median of 20.9 months at the time of the data cutoff.
The researchers found that rPFS was significantly improved with 177Lu-PSMA-617 and SOC versus SOC alone (median, 8.7 versus 3.4 months; hazard ratio, 0.40). There was also significant improvement in the alternate primary end point of overall survival (median, 15.3 versus 11.3 months; hazard ratio, 0.62). There was a statistically significant difference between the treatment arms in favor of 177Lu-PSMA-617 plus SOC for all key secondary end points. Therapy was well tolerated, although the rate of high-grade treatment-emergent adverse events was higher with 177Lu-PSMA-617 (52.7 versus 38 percent).
“The findings suggest that 177Lu-PSMA-617 warrants consideration as a new standard of care in this patient population, pending regulatory review and approval,” Morris said in a statement.
The study was funded by Endocyte Inc., a Novartis company; several authors disclosed ties to the pharmaceutical industry.
ESMO: Combination Treatment Improves Survival in Muscle-Invasive Bladder Cancer
Mivocabtagene Autoleucel Shows Promise in Stiff Person Syndrome
Broad Genomic Sequencing Improves Survival in First-Line Setting in Advanced NSCLC
1975 to 2017 Saw Increases in Survival for Children With Cancer
Early Survivorship Care Linked to Improved Outcomes in Head, Neck Cancer
Exercise Intervention Linked to Improved Attention, Memory in Breast Cancer
Cancer Survivors Have Lower Levels of Physical Activity
Childhood Cancer Survivors Often Have Mental Distress in Adulthood